| UHC Commercial Medical & Drug | Oxlumo® (Lumasiran) and Rivfloza® (Nedosiran) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Commercial Medical & Drug | Skyrizi® (Risankizumab-Rzaa) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Commercial Medical & Drug | Tremfya® (Guselkumab) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Commercial Medical & Drug | White Blood Cell Colony Stimulating Factors – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Commercial Medical & Drug | Xolair® (Omalizumab) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| Meridian Illinois Medicaid Clinical | Electric Tumor Treating Fields (Optune) | 2025-10-01 |
| Meridian Illinois Medicaid Clinical | Mechanical Stretching Devices for Joint Stiffness | 2025-10-01 |
| Meridian Illinois Medicaid Clinical | Pediatric Oral Function Therapy | 2025-10-01 |
| Meridian Illinois Medicaid Clinical | Stereotactic Body Radiation Therapy | 2025-10-01 |
| Meridian Illinois Medicaid Clinical | Transplant Service Documentation Requirements | 2025-10-01 |